Global Breast Cancer Therapeutics Market Forecast to 2023; Led by AstraZeneca, Eli Lilly, F. Hoffmann-La Roche, Novartis and Pfizer - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 4, 2019--The “Global Breast Cancer Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The breast cancer therapeutics market will register a CAGR of close to 8% by 2023.
Emerging novel therapies to gain traction in the market
Therapies including combination therapies, vaccines, PARP inhibitors, and CDK inhibitors are emerging as innovative approaches to treat breasts cancer.
Rising number of patient supportive initiatives
To address the economic and emotional burden associated with cancer, manufacturers, governments, non-profit organizations, and healthcare providers are aiming at improving patient access to resources and bridge the substantial gaps in care.
Tendency of patients to prefer substitutes
Individuals with breast cancer often opt for mastectomy, lumpectomy, and radiation therapy to eliminate the tumor mass. However, efficient therapies including chemotherapy, and targeted and hormonal therapies are used to treat breast cancer. These surgeries act as substitutes and patients prefer these substitutes, which are expensive and can have a series of side effects.
Key PlayersAstraZeneca Eli Lilly F. Hoffmann-La Roche Novartis Pfizer
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZINGMarket definition Market sizing 2018 Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY PRODUCTMarket segmentation by product Comparison by product Targeted therapy - Market size and forecast 2018-2023 Hormonal therapy - Market size and forecast 2018-2023 Chemotherapy - Market size and forecast 2018-2023 Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPEDuctal carcinoma in situ Invasive Ductal Carcinoma Triple-negative breast cancer Inflammatory breast cancer Metastatic breast cancer
PART 10: GEOGRAPHIC LANDSCAPEGeographic segmentation Geographic comparison Americas - Market size and forecast 2018-2023 EMEA - Market size and forecast 2018-2023 APAC - Market size and forecast 2018-2023 Key leading countries Market opportunity
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPEOverview Landscape disruption
PART 14: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors AstraZeneca Eli Lilly F. Hoffmann-La Roche Novartis Pfizer
For more information about this report visit https://www.researchandmarkets.com/research/vc65jq/global_breast?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190104005406/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Breast Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/04/2019 11:44 AM/DISC: 01/04/2019 11:44 AM